{
  "first_published_at": "2010-07-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON088174", 
  "title": "Orciprenaline sulphate (Alupent): reminder of withdrawal from the market on Sept 30, 2010", 
  "tags": "{\"parsed_therapeutic\": [\"respiratory-disease-allergy\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Respiratory disease and allergy\"]}", 
  "_document_number": 193, 
  "label": "Reminder", 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/withdrawal_icon.png", 
  "therapeutic_area": [
    "respiratory-disease-allergy"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Orciprenaline sulphate (Alupent): reminder of withdrawal from the market on Sept 30, 2010</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: July 2010</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--Please ensure that patients are transferred to alternative bronchodilator therapy.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Please ensure that patients are transferred to alternative bronchodilator therapy.</p><p><strong>Orciprenaline sulphate</strong> (Alupent syrup), a non-specific &#946;-agonist, was formerly licensed for reversible airway obstruction and suggested for maintenance therapy. It is to be withdrawn from the UK market on Sept 30, 2010. A comprehensive analysis of the available literature was completed last year, which showed that it was significantly less efficacious than other more-specific &#946;<sub>2</sub><font class=\"normal\">-</font>agonists and was associated with a higher incidence of side effects. The review concluded that the risk-benefit balance was unfavourable. Accordingly, the Commission on Human Medicines concluded that there:</p><ul>\r\n\t\t\t<li>should be a planned withdrawal of orciprenaline sulphate from the UK market</li>\r\n\t\t\t<li>are no patient groups for whom transfer to a more-selective &#946;<sub>2</sub>-agonist would be inappropriate</li></ul><p>Orciprenaline sulphate will no longer be available after Sept 30, 2010. All patients who are currently receiving this medicine should be switched to a more-selective short-acting &#946;<sub>2</sub>-agonist such as salbutamol or terbutaline as soon as possible.</p><p><a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON062529\" title=\"Orciprenaline sulphate: Planned withdrawal from the UK market following a risk-benefit analysis\">Orciprenaline sulphate: Planned withdrawal from the UK market following a risk-benefit analysis</a></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update July 2010, vol 3 issue 12: 5a.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Please ensure that patients are transferred to alternative bronchodilator therapy.</p><p><strong>Orciprenaline sulphate</strong> (Alupent syrup), a non-specific &#946;-agonist, was formerly licensed for reversible airway obstruction and suggested for maintenance therapy. It is to be withdrawn from the UK market on Sept 30, 2010. A comprehensive analysis of the available literature was completed last year, which showed that it was significantly less efficacious than other more-specific &#946;<sub>2</sub><font class=\"normal\">-</font>agonists and was associated with a higher incidence of side effects. The review concluded that the risk-benefit balance was unfavourable. Accordingly, the Commission on Human Medicines concluded that there:</p><ul>\r\n\t\t\t<li>should be a planned withdrawal of orciprenaline sulphate from the UK market</li>\r\n\t\t\t<li>are no patient groups for whom transfer to a more-selective &#946;<sub>2</sub>-agonist would be inappropriate</li></ul><p>Orciprenaline sulphate will no longer be available after Sept 30, 2010. All patients who are currently receiving this medicine should be switched to a more-selective short-acting &#946;<sub>2</sub>-agonist such as salbutamol or terbutaline as soon as possible.</p><p><a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON062529\" title=\"Orciprenaline sulphate: Planned withdrawal from the UK market following a risk-benefit analysis\">Orciprenaline sulphate: Planned withdrawal from the UK market following a risk-benefit analysis</a></p><p>&#160;</p><p><em>Article citation: Drug Safety Update July 2010, vol 3 issue 12: 5a.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2010-07-01", 
  "date_last_modified": "2010-09-14", 
  "_assets": [], 
  "_item_id": 193, 
  "summary": "", 
  "body": "Article date: July 2010\n\nPlease ensure that patients are transferred to alternative bronchodilator therapy.\n\nOrciprenaline sulphate (Alupent syrup), a non-specific β-agonist, was formerly licensed for reversible airway obstruction and suggested for maintenance therapy. It is to be withdrawn from the UK market on Sept 30, 2010. A comprehensive analysis of the available literature was completed last year, which showed that it was significantly less efficacious than other more-specific β2-agonists and was associated with a higher incidence of side effects. The review concluded that the risk-benefit balance was unfavourable. Accordingly, the Commission on Human Medicines concluded that there:  \n  \n  * should be a planned withdrawal of orciprenaline sulphate from the UK market  \n  * are no patient groups for whom transfer to a more-selective β2-agonist would be inappropriate  \n  \nOrciprenaline sulphate will no longer be available after Sept 30, 2010. All patients who are currently receiving this medicine should be switched to a more-selective short-acting β2-agonist such as salbutamol or terbutaline as soon as possible.\n\n[Orciprenaline sulphate: Planned withdrawal from the UK market following a risk-benefit analysis](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON062529)\n\n \n\nArticle citation: Drug Safety Update July 2010, vol 3 issue 12: 5a.\n"
}